TSX gains after CPI shows US inflation rose 3%
Investing.com - H.C. Wainwright raised its price target on Microbot Medical (NASDAQ:MBOT) to $12.00 from $9.00 on Thursday, while maintaining a Buy rating on the medical robotics company. The stock has shown remarkable momentum, delivering a 218.75% return year-to-date according to InvestingPro data.
The upgrade follows the FDA’s 510(k) clearance for Microbot’s LIBERTY System, which the firm described as the first FDA-approved, single-use, remotely operated robotic system for peripheral endovascular procedures. Management plans to begin U.S. commercialization in the fourth quarter of 2025.
The LIBERTY System demonstrated 100% success in robotic navigation to target areas with zero device-related adverse events in its pivotal study. The system also showed a 92% relative reduction in radiation exposure for physicians during procedures.
H.C. Wainwright noted that the initial addressable market comprises approximately 2.5 million peripheral endovascular procedures annually in the U.S. The firm highlighted that hospitals using LIBERTY would no longer need dedicated infrastructure and capital equipment to access advanced robotics.
The research firm estimates Microbot Medical’s current market value at $545 million, supporting its new $12 price target, and considers the company one of its top picks for the second half of 2025.
In other recent news, Microbot Medical Inc. has received FDA clearance for its LIBERTY Endovascular Robotic System, marking it as the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. This regulatory milestone positions the company to begin commercialization in the U.S. market by the fourth quarter of 2025. Additionally, Microbot Medical has raised approximately $5.9 million through the issuance of nearly 3 million shares from the exercise of various preferred investment options. The company also maintained its Buy rating and $9.00 price target at H.C. Wainwright following the grant of a new patent for its LIBERTY system. This patent covers a modular robotic surgical system with a base and multiple tool-receiver units. Furthermore, CEO Harel Gadot presented the LIBERTY System at the H.C. Wainwright Annual Investor Conference, highlighting its unique features. In related developments, Harel Gadot has been appointed as an independent director to the board of Brenmiller Energy Ltd. These recent developments underscore Microbot Medical’s ongoing advancements and strategic moves in the medical technology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.